All News
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
MedPage Today
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Read Article
Lupus Mortality Risk in Young Women
ACR
New research using death certificate data from 52,942 females, reveals that systemic lupus erythematosus (lupus) is a leading cause of years of potential life lost among young women in the United States, underscoring the disease’s significant and often underrecognized public health burden.
Read Article
Chronic Low Back Pain Disappointments in a Randomized Trial
Annals of Internal Medicine reports that patients with chronic low back pain (cLBP) may benefit from physical therapy (PT); but when that fails, other secondary measures (cognitive behavioral therapy (CBT) or mindfulness) may not be effective.
Read Article
Vitamin D in Rheumatic Disease - is it Good Enough?
Vitamin D deficiency or insufficiency of is highly prevalent and has been often associated with inflammatory rheumatic diseases, raising the question of whether inadequate vitamin D status contributes to immune dysregulation, incipient disease, increased disease activity, or poor skeletal outco
Read Article
Vitamin D in Rheumatic Disease - Is It Good Enough?
Vitamin D in rheumatic disease — is it sufficient? Vitamin D deficiency/insufficiency is common and linked to inflammatory rheumatic diseases, raising the question of whether low vitamin D drives immune dysregulation, disease https://t.co/CLBFii2TbR
Dr. John Cush RheumNow ( View Tweet)
🚨 SAVE THE DATE
June 3–6, 2026
RheumNow is bringing you real-time coverage of #EULAR2026
👉 Breaking data
👉 Late-breakers
👉 Global expert insights
Don’t miss a moment. #Rheumatology https://t.co/hqmIdeoS4H
Dr. John Cush RheumNow ( View Tweet)
Femoral BMD & osteoporosis are independent predictors (nverse relationship) of all-cause mortality in postmenopausal women. NHANES study(2005-2018) of 2,977 postmenopausal F, OP yielded 47% incr mortality (HR 1.47) https://t.co/67Jv63X0Hx https://t.co/4vbFDydTY7
Dr. John Cush RheumNow ( View Tweet)
APR: Still's Disease
Companion slide deck for the Advanced Practice Rheum: Still's Disease and Fever video, featuring Dr. Jack Cush.
https://t.co/wsUP2zEulC https://t.co/AWSNt9Uzlg
Dr. John Cush RheumNow ( View Tweet)
Influential Rheumatoid Factors (5.8.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/BaugLQEIai https://t.co/WdWXAfB5lk
Dr. John Cush RheumNow ( View Tweet)
Parvovirus B19 Infection - Images from JAMA Dermatology. 40yoM 2-days asymptomatic rash w/ fever to 39°C, w/ arthralgias, Rash on BL cheeks, inguinal, flanks, axilla. WBC =2K, CRP 1.24 mg/dl. Dx by PCR for parvovirus B19 DNA https://t.co/LGGnabvFvA https://t.co/yyBF9pEGls
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of renal crisis & pulm. arterial HTN (PAH) in systemic sclerosis - retrospect. study of 234 SSc pts; 7.3% had PAH & SRC. PAH may precede overlap w/ SRC. SSc w/ both at hi risk for GI bleed (OR 9.5). SRC+PAH assoc w/ Older age, elevated NT-proBNP https://t.co/MsaiPdcDrb https://t.co/CyMrL8izxP
Dr. John Cush RheumNow ( View Tweet)
Dr. Robert Terkeltaub walks through the evolution of gout at #RheumNowLive 2026.
🎧 Listen here: https://t.co/S6RXQo2Umt
#Gout #Rheumatology #MedEd https://t.co/XDbTmj3MOw
Dr. John Cush RheumNow ( View Tweet)
No link between pregnancy tylenol & autism. JAMA Pediatrics data from 1.5 million Danish children( 1997 -2022); ~2% were tylenol exposed during preg. 2% of these Dx w/ Dx w/ autism (vs. 3% not exposed) https://t.co/Pp1tE54Dic https://t.co/qu61jKolpN
Dr. John Cush RheumNow ( View Tweet)
FDA has published final guidance on Postapproval Pregnancy Safety Studies; how to study outcomes in pregnant women exposed to drugs & biologics- updates on registries,statistical methods, complementary studies, rare Rx exposures https://t.co/NWxrgB0dPQ https://t.co/ckyaJ07MQ0
Dr. John Cush RheumNow ( View Tweet)
ANCA assoc. pachymeningitis (AAP) is rare. 230 systemic vasculitis, from 177 reports (108 MPO+, 71 PR3+); age~60; HA & cranial neuropathy (hearing/visual loss, diplopia) common. 89% w/ systemic Sxs (ENT, lungs, orbits, kidneys). Look for abnl ESR/CRP, CSF https://t.co/bHQegYYl5V https://t.co/hpfu8iaIkx
Dr. John Cush RheumNow ( View Tweet)
CorEvitas RA registry study of 9601 RA pts starting b/tsDMARDs (52K yrs F/U) - 10.4% had eGFR<60 9CRI). Achieving CDAI remission was lower w/ CRI - 28% vs 19%(adj HR 0·76 [0·66–0·88]) https://t.co/E42N3PQHwG https://t.co/WNIGGCpCfZ
Dr. John Cush RheumNow ( View Tweet)
Gout Control Lowers Cardiovascular Events
A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.
https://t.co/LcBg7yCw4c https://t.co/dBYdnq9XLJ
Dr. John Cush RheumNow ( View Tweet)
A Review of Hydroxychloroquine Ocular Toxicity
While HCQ is thought to be a very safe drug, its ocular risk profile is probably more serious than appreciated. A comprehensive review published in the Journal of Rheumatology discusses HCQ pharmacokinetics, mechanisms of retinal https://t.co/BrENoaBAVx
Dr. John Cush RheumNow ( View Tweet)
This is the book of my origins in Medicine; my medical school, St. Georges University (#SGU) that I went to in 1977. A great stroy of unlikely characters, with shared missions and dreams that developed me and thousands of other great Physicians who dramatically changed medical https://t.co/zGZXt6qcUm
Dr. John Cush RheumNow ( View Tweet)
